Zealand Pharma A/S
Zealand convenes for the Annual General Meeting 2015

Zealand Pharma A/S 

26.03.2015 14:43

Dissemination of a Adhoc News, transmitted by DGAP - a service of EQS Group
AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Copenhagen, 2015-03-26 14:43 CET (GLOBE NEWSWIRE) -- Copenhagen, 26 March 2015
‐ Zealand Pharma A/S (Zealand) (Nasdaq Copenhagen: ZEAL) convenes for its
ordinary Annual General Meeting for 2015. 

The Annual General Meeting will be held on:

Tuesday 21 April 2015 at 3.00pm CET,

at the offices of Plesner Law Firm, Amerika Plads 37, 2100 Copenhagen Ø,
Denmark. 

After the Annual General Meeting, Zealand will be hosting a light buffet
including refreshments, where Zealand's management team will be present for
discussion and to answer questions. The notice to convene for the Annual
General Meeting including the full agenda is enclosed as appendix to this
announcement and the following should be noted: 

Agenda item no. 4: Election of members to the Board of Directors

All board members elected by the General Meeting are elected on an annual basis.

Chairman Daniël Jan Ellens and Vice Chairman Jørgen Lindegaard do not stand for
re-election. 

The Board of Directors proposes the re-election of:

  -- Peter Benson
  -- Alain Munoz
  -- Michael J. Owen

In addition, the Board of Directors proposes that the following are elected as
new members of the Board of Directors: 

  -- Rosemary Crane
  -- Catherine Moukheibir
  -- Martin Nicklasson

The proposed candidates are recommended by the Nomination Committee. Motivation
for the recommendations is included in the enclosed notice to convene, which
also presents a description of all candidates for the Board of Directors in
Exhibit 1. 



                                      ●●●●●

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, email: bmj@zealandpharma.com

Hanne Leth Hillman, Senior Vice President for Communications and Investor
Relations 
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com



About Zealand Pharma

Zealand Pharma A/S ('Zealand') (Nasdaq Copenhagen: ZEAL) is a biotechnology
company based in Copenhagen, Denmark. Zealand has leading expertise in the
discovery, design and development of novel peptide medicines and possesses
in-house competences in clinical trial design and management with a therapeutic
focus on metabolic diseases and acute care indications. The company is
advancing a pipeline of novel wholly-owned medicines alongside a partnered
product and development portfolio. 

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as
Lyxumia(R) and in Phase III development as a single-injection combination with
Lantus(R) (LixiLan), both under a global license agreement with Sanofi. US
regulatory submission of Lyxumia(R) is planned for Q3 2015 and US/EU regulatory
submissions for LixiLan in Q4 2015. 

Zealand's wholly-owned products include danegaptide (prevention of Ischemic
Reperfusion Injury) in Phase II and the stable glucagon product, ZP4207
(treatment of severe hypoglycemia) in Phase I as well as several preclinical
peptide therapeutics. Partnering represents an important component of strategy
to leverage in-house expertise, share development risk in large clinical
trials, provide funding and commercialize the company's products. Zealand
currently has global license agreements and partnerships with Sanofi, Helsinn
Healthcare, Boehringer Ingelheim and Eli Lilly. 

For further information: www.zealandpharma.com         Follow us on Twitter
@ZealandPharma 



       Indkaldelse                   Notice          
           til                     to convene        
ordinær generalforsamling  the Annual General Meeting
   i Zealand Pharma A/S       of Zealand Pharma A/S  
  (CVR-nr. 20 04 50 78)       (CVR no. 20 04 50 78)  
      ('Selskabet')             ('the Company')      



Selskabets bestyrelse indkalder        The Board of Directors of the Company    
 hermed til ordinær generalforsamling   hereby convenes the Annual General      
 i Selskabet, der afholdes              Meeting of the Company to be held on    
                                                                                
   Tirsdag, 21. april 2015 kl. 15           Tuesday, 21 April 2015 at 3 pm.     
                                                                                
hos Plesner advokatfirma, Amerika      at the offices of Plesner Law Firm,      
 Plads 37, 2100 København Ø, Danmark.   Amerika Plads 37, 2100 Copenhagen Ø,    
                                        Denmark.                                
                                                                                
Dagsorden:                             Agenda:                                  
                                                                                
(1)      Bestyrelsens beretning om     A report from the Board of Directors on  
 Selskabets virksomhed i det forløbne   the Company's activities in the past    
 regnskabsår                            financial year                          
(2)      Godkendelse af den            Approval of the audited Annual Report    
 reviderede årsrapport                                                          
                                                                                
(3)      Beslutning om anvendelse af   A resolution on the distribution of      
 overskud eller dækning af underskud    profit or the cover of loss in          
 i henhold til den godkendte            accordance with the approved Annual     
 årsrapport                             Report                                  
                                                                                
(4)      Valg af medlemmer til         Election of members of the Board of      
 bestyrelsen                            Directors                               
(5)      Valg af revisor               Appointment of auditor                   
                                                                                
(6)      Bemyndigelse til erhvervelse  Authorisation to acquire the Company's   
 af egne aktier                         own shares                              
                                                                                
(7)      Forslag fra bestyrelsen om    Proposal from the Board of Directors to  
 ændring af generelle retningslinjer    adjust the general guidelines for       
 for incitamentsaflønning af            incentive remuneration to the Management
 Selskabets ledelse                     of the Company                          
(8)      Forslag fra bestyrelsen om    Proposal from the Board of Directors to  
 ændring af Selskabets                  adjust the remuneration policy of the   
 vederlagspolitik                       Company                                 
(9)      Forslag fra bestyrelsen om    Proposal from the Board of Directors to  
 godkendelse af bestyrelsens vederlag   approve the fee to the Board of         
 for regnskabsåret 2015                 Directors for the financial year 2015   
(10)   Forslag fra bestyrelsen om      Proposal from the Board of Directors to  
 godkendelse af ny bemyndigelse til     approve a new authorisation to issue    
 at udstede warrants samt ændring af    warrants and amendment of the Company's 
 Selskabets vedtægter i                 articles of association in accordance   
 overensstemmelse hermed                therewith                               
(11)   Eventuelt                       Any other business                       
                                                                                
Fuldstændige forslag:                  Complete proposals:                      
                                                                                
Ad punkt 2:                            Re item 2:                               
Bestyrelsen foreslår, at årsrapporten  The Board of Directors proposes that the 
 godkendes.                             Annual Report be approved.              
Ad punkt 3:                            Re item 3:                               
Bestyrelsen foreslår årets resultat    The Board of Directors proposes that the 
 bestående af et underskud på DKK       result of the year, i.e. a loss of DKK  
 64.989.794 overført til næste år.      64,989,794 be carried forward to next   
                                        year.                                   
                                                                                
Ad punkt 4:                            Re item 4:                               
De af generalforsamlingen valgte       All board members elected by the General 
 bestyrelsesmedlemmer vælges på         Meeting are elected on an annual basis. 
 årsbasis.                             Daniël Jan Ellens, Jørgen Lindegaard and 
Daniël Jan Ellens, Jørgen Lindegaard    Florian Renaud do not stand for         
 og Florian Renaud stiller ikke op      re-election.                            
 til genvalg.                          The Board of Directors proposes          
Bestyrelsen foreslår genvalg af:        re-election of:                         
-- Peter Benson                        -- Peter Benson                          
-- Alain Munoz                         -- Alain Munoz                           
-- Michael J. Owen                     -- Michael J. Owen                       
Herudover foreslår bestyrelsen valg    In addition, the Board of Directors      
 af følgende som nye medlemmer af       proposes the election of the following  
 bestyrelsen:                           as new members of the Board of          
-- Rosemary Crane                       Directors:                              
-- Catherine Moukheibir                -- Rosemary Crane                        
-- Martin Nicklasson                   -- Catherine Moukheibir                  
Nomineringskomitéen anbefaler valg     -- Martin Nicklasson                     
 af:                                   The nomination committee recommends      
Rosemary Crane, på grund af hendes      election of:                            
 betydelige kendskab til det globale   Rosemary Crane because of her extensive  
 kommercielle marked for lægemidler,    commercial knowledge of the global      
 specielt med stor viden om det         pharmaceutical market, in particular    
 amerikanske marked; Catherine          with a strong US experience; Catherine  
 Moukheibir på grund af hendes          Moukheibir because of her deep knowledge
 betydelige finansielle forståelse af   of investment banking and               
 og erfaring med biotekindustrien og    accounting/reporting within the biotech 
 Martin Nicklasson på grund af hans     industry and Martin Nicklasson because  
 brede industrierfaring fra             of his profound executive experience    
 topledelse af europæiske lægemiddel-   from European pharmaceutical and biotech
 og biotekselskaber.                    companies.                              
For en beskrivelse af de opstillede    For a description of the nominated       
 kandidaters baggrund se Bilag 1 til    candidates see Exhibit 1 to this notice.
 indkaldelsen.                                                                  
Ad punkt 5:                            Re item 5:                               
Bestyrelsen foreslår genvalg af        The Board of Directors proposes          
 Deloitte Statsautoriseret              re-election of Deloitte Statsautoriseret
 Revisionspartnerselskab.               Revisionspartner-selskab.               
                                                                                
Ad punkt 6:                            Re item 6:                               
Bestyrelsen anmoder om                 The Board of Directors requests the      
 generalforsamlingens bemyndigelse      General Meeting to authorize the Company
 til, at Selskabet i tiden indtil       to acquire - in the period until the    
 næste ordinære generalforsamling kan   next Annual General Meeting - the       
 erhverve egne aktier inden for en      Company's own shares in a nominal amount
 samlet pålydende værdi af i alt 10     of up to 10 per cent of the Company's   
 pct. af Selskabets til enhver tid      share capital from time to time provided
 værende aktiekapital, forudsat at      that the acquisition, pursuant to the   
 erhvervelsen i henhold til             Danish Companies Act section 197, can be
 selskabsloven § 197 kan finansieres    financed by funds that may be           
 med midler, der kan anvendes til       distributed as ordinary dividends. The  
 ordinært udbytte. Vederlaget må ikke   payment may not deviate from the share  
 afvige fra den på                      price quoted at NASDAQ OMX Copenhagen   
 erhvervelsestidspunktet på NASDAQ      A/S at the time of purchase with more   
 OMX Copenhagen A/S noterede børskurs   than 10 per cent.                       
 med mere end 10 pct.                                                           
                                                                                
Ad punkt 7:                            Re item 7:                               
Bestyrelsen foreslår, at               The Board of Directors proposes that the 
 generalforsamlingen godkender          General Meeting approves updated general
 opdaterede generelle retningslinjer    guidelines for incentive remuneration to
 for incitamentsaflønning af            the Management of the Company. The      
 Selskabets ledelse, således at         updated guidelines entail that the      
 retningslinjerne ændres til, at det    guidelines are changed so that share    
 tidligste tidspunkt for udnyttelsen    rights/warrants may be exercised one    
 af aktiekøberetter/warrants er et år   year after granting, as opposed to the  
 mod tidligere tre år efter             previous three years. Additionally, a   
 tildeling. Derudover foretages         few editorial amendments have been made 
 enkelte redaktionelle ændringer i      to the guidelines.                      
 retningslinjerne.                     The proposal for the updated general     
Forslag til de opdaterede generelle     guidelines for incentive remuneration to
 retningslinjer for                     the Management of the Company           
 incitamentsaflønning af Selskabets     (track-changes version) will be         
 ledelse (ændringsmarkeret version)     available from 26 March 2015 on the     
 er fra den 26. marts 2015              website of the Company,                 
 tilgængelig på Selskabets              www.zealandpharma.com.                  
 hjemmeside, www.zealandpharma.com.    Re item 8:                               
Ad punkt 8:                            The Board of Directors proposes that the 
Bestyrelsen foreslår, at                General Meeting approves updated        
 generalforsamlingen godkender          remuneration policy for the Board of    
 opdateret vederlagspolitik for         Directors and the Executive Management  
 bestyrelsen og direktionen, således    to reflect that there is no severance   
 at den afspejler, at ingen medlemmer   pay for the members of the Executive    
 af direktionen modtager                Management.                             
 fratrædelsesgodtgørelse.              The proposal for the updated remuneration
Forslag til den opdaterede              policy (track-changes version) will be  
 vederlagspolitik (ændringsmarkeret     available from 26 March 2015 on the     
 version) er fra den 26. marts 2015     website of the Company,                 
 tilgængelig på Selskabets              www.zealandpharma.com.                  
 hjemmeside, www.zealandpharma.com.    Re item 9:                               
Ad punkt 9:                            The Board of Directors proposes that the 
Bestyrelsen foreslår, at                General Meeting approves the fee to the 
 generalforsamlingen godkender          Board of Directors for the financial    
 bestyrelsens vederlag for              year 2015.                              
 regnskabsåret 2015.                   The Board of Directors proposes that, as 
Bestyrelsen foreslår, i lighed med      last year, board members receive a fixed
 sidste år, at bestyrelsesmedlemmer     cash amount of DKK 150,000, the Chairman
 modtager et fast kontant honorar på    receives DKK 450,000, the Vice Chairman 
 DKK 150.000, bestyrelsesformanden      receives DKK 300,000 and the Chairman of
 modtager DKK 450.000, bestyrelsens     the Audit Committee receives DKK 300,000
 næstformand modtager DKK 300.000, og   per year.                               
 formanden for revisionsudvalget       Currently, the Chairman of the Board of  
 modtager DKK 300.000 pr. år.           Directors and the employee elected board
På nuværende tidspunkt deltager         members participate in incentive        
 formanden for bestyrelsen og de        programs, based on the development of   
 medarbejdervalgte                      the Company's share price, as described 
 bestyrelsesmedlemmer i                 in note 14 in the 2014 Annual Report.   
 incitamentsprogrammer baseret på      Currently, no other board members receive
 udviklingen af Selskabets aktiekurs,   share based incentive remuneration.     
 som beskrevet i note 14 i                                                      
 årsrapporten for 2014.                                                         
Ingen andre bestyrelsesmedlemmer                                                
 mod-tager på nuværende tidspunkt                                               
 aktiebaseret incitamentsaflønning.                                             
Ad punkt 10:                           Re item 10:                              
Bestyrelsen foreslår, at               The Board of Directors proposes that the 
 generalforsamlingen godkender en ny    General Meeting approves an             
 bemyndigelse til bestyrelsen til at    authorisation to the Board of Directors 
 udstede warrants i overensstemmelse    to issue warrants in accordance with the
 med følgende bestemmelser, der         following provisions to be inserted in  
 indsættes i Selskabets vedtægter som   the Company's articles of association as
 punkterne 8.4-8.6:                     sections 8.4-8.6:                       
8.4 Bestyrelsen er i perioden indtil   During the period until 21 April 2020 the
 den 21. april 2020 bemyndiget til ad   board of directors is autho­rized to    
 en eller flere gange at udstede        issue at one or more times warrants with
 warrants med ret til at tegne op til   a right to subscribe for shares up to an
 nominelt DKK 2.750.000 aktier i        aggregate amount of nominally DKK       
 Selskabet. Selskabets aktionærer       2,750,000 shares in the Company. The    
 skal ikke have fortegningsret ved      shareholders of the Company will not    
 bestyrelsens udnyttelse af denne       have pre-emptive subscription rights    
 bemyndigelse. De nærmere vilkår        when the Board of Directors exercises   
 fastsættes af bestyrelsen.             this authorization. The specific terms  
 Bestyrelsen fastsætter selv            and conditions in this respect are to be
 udnyttelseskursen samt øvrige vilkår   determined by the Board of Directors.   
 for warrants, dog således at           The Board of Directors determines, at   
 udnyttelseskursen som minimum skal     its own discretion, the exercise price  
 svare til markedskursen på             as well as other terms and conditions   
 tidspunktet for udstedelsen af         for the warrants, always provided that  
 warrants, medmindre disse udstedes     the exercise price as a minimum         
 til Selskabets medarbejdere.           corresponds to the market price at the  
Bestyrelsen kan efter de til enhver     time of issuance of the warrants, unless
 tid gældende regler i selskabsloven    these are issued to the Company's       
 genanvende eller genudstede            employees.                              
 eventuelle bortfaldne ikke udnyttede  Pursuant to the provisions of the Danish 
 warrants, forudsat at genanvendelsen   Companies Act in force from time to     
 eller genudstedelsen finder sted       time, the Board of Directors may reapply
 inden for de vilkår og tidsmæssige     or reissue any lapsed non-exercised     
 begrænsninger, der fremgår af denne    warrants, provided that such            
 bemyndigelse. Ved genanvendelse        reapplication or reissue is made under  
 forstås adgangen for bestyrelsen til   the terms and conditions and within the 
 at lade en anden aftalepart indtræde   time limits specified under this        
 i en allerede bestående aftale om      authority. Reapplication means the right
 warrants. Ved genudstedelse forstås    of the Board of Directors to let another
 bestyrelsens mulighed for inden for    contractual party become a party to an  
 samme bemyndigelse at genudstede nye   already existing agreement on warrants. 
 warrants, hvis allerede udstedte       Reissue means the possibility for the   
 warrants er bortfaldet.                Board of Directors to reissue new       
Bestyrelsen er i perioden indtil den    warrants under the same authorization if
 21. april 2020 endvidere bemyndiget    those already issued have lapsed.       
 til ad en eller flere gange at        During the period until 21 April 2020,   
 forhøje Selskabets aktiekapital med    the Board of Directors is also          
 op til nominelt DKK 2.750.000 aktier   authorized to increase at one or more   
 ved kontant indbetaling i              times the Company's share capital by up 
 forbindelse med udnyttelse af          to nominally DKK 2,750,000 shares by    
 warrants eller et sådant beløb som     cash payment in connection with the     
 måtte følge af en eventuel             exercise of the warrants or such an     
 regulering af antallet af warrants     amount caused by an adjustment (if any) 
 ved ændringer i Selskabets             in the number of warrants due to changes
 kapitalforhold. Selskabets             in the capital structure, without       
 aktionærer skal ikke have              pre-emptive subscription rights for the 
 fortegningsret til aktier som          shareholders of the Company to shares   
 udstedes ved udnyttelse af udstedte    issued by exercise of the issued        
 warrants.                              warrants.                               
8.5 Alle aktier, der tegnes ved        8.5 The shares subscribed for by exercise
 udnyttelse af warrants udstedt i       of the warrants issued pursuant to      
 henhold til § 8.4, skal være           article 8.4 shall be negotiable         
 omsætningspapirer og navneaktier og    instruments and issued in the holder's  
 noteres i Selskabets ejerbog.          name and shall be registered in the     
De nye aktier skal være ligestillet     Company's Register of Shareholders.     
 med den bestående aktiekapital.       The new shares shall have the same rights
 Ingen aktionær skal være forpligtet    as the existing shares of the Company.  
 til at lade sine aktier indløse helt   No shareholder shall be obliged to have 
 eller delvist. De nye aktier skal      the shares redeemed fully or partly. The
 give ret til udbytte og andre          new shares shall give rights to         
 rettigheder i Selskabet fra det        dividends and other rights in the       
 tidspunkt, som fastsættes af           Company from the time which is          
 bestyrelsen i                          determined by the Board of Directors in 
 forhøjelsesbeslutningen.               connection with the decision to increase
8.6 Bestyrelsen er bemyndiget til at    the share capital.                      
 ændre nærværende vedtægter i          8.6 The Board of Directors is authorized 
 tilfælde af udnyttelse af de givne     to amend these Articles of Association  
 bemyndigelser eller warrants.          as a consequence of applying the        
                                        authorizations granted or the exercise  
                                        of warrants.                            
                - 0 -                                    - 0 -                  
                                                                                
Sprog:                                 Language:                                
Generalforsamlingen afholdes på        The General Meeting is held in English   
 engelsk uden tolkning til dansk.       without any translation into Danish.    
                                                                                
Vedtagelseskrav:                       Resolution requirements:                 
Der gælder følgende vedtagelseskrav    The following requirements apply to pass 
 for forslagene, der alle skal være     the resolutions which must all be       
 opfyldte for, at forslagene kan        fulfilled in order for the proposals to 
 anses som vedtaget:                    be adopted:                             
Forslagene i henhold til dagsordenens  The proposals set out in items 2 - 9 of  
 punkt 2 - 9 kan vedtages med simpelt   the agenda must be adopted by a simple  
 stemmeflertal. Til vedtagelse af       majority of votes. The adoption of the  
 forslaget under punkt 10 kræves, at    proposal under item 10 requires that the
 forslaget vedtages af mindst 2/3 af    proposal is adopted by at least         
 de afgivne stemmer samt af mindst      two-thirds of the votes cast as well as 
 2/3 af aktiekapitalen repræsenteret    at least two-thirds of the share capital
 på generalforsamlingen.                represented at the General Meeting.     
                                                                                
                - 0 -                                    - 0 -                  
                                                                                
Generelle oplysninger                  General information                      
Selskabets aktiekapital er på          The share capital of the Company is      
 nominelt DKK 23.313.880. Hver akties   nominally DKK 23,313,880. The nominal   
 pålydende er DKK 1. På                 amount of each share is DKK 1. Each     
 generalforsamlingen giver hvert        share of DKK 1 has one vote at the      
 aktiebeløb på DKK 1 en stemme.         General Meeting.                        
                                                                                
Aktionærer kan udøve deres             The shareholders may exercise their      
 finansielle rettigheder gennem egen    financial rights through their own      
 depotbank.                             depositary bank.                        
                                                                                
Selskabets hjemmeside                  The website of the Company               
Der vil i perioden fra den 26. marts   Further information will be available    
 2015 til den 21. april 2015 på         from 26 March 2015 to 21 April 2015 on  
 Selskabets hjemmeside,                 the website of the Company,             
 www.zealandpharma.com, kunne findes    www.zealandpharma.com, concerning the   
 yderligere oplysninger om              General Meeting, including the total    
 generalforsamlingen, herunder det      number of shares and voting rights on   
 samlede antal aktier og                the date of the notice, the notice with 
 stemmerettigheder på datoen for        the agenda and the complete proposals, a
 indkaldelsen, indkaldelsen med         proxy form, a postal vote form and a    
 dagsorden og de fuldstændige           registration form to be used when       
 forslag, fuldmagtsblanket,             ordering an admission card as well as   
 brevstemmeblanket og                   the other documents to be presented at  
 tilmeldingsblanket samt de øvrige      the General Meeting, including the      
 dokumenter, der skal fremlægges på     Annual Report, draft revised Articles of
 generalforsamlingen, herunder          Association, draft updated general      
 årsrapporten, udkast til reviderede    guidelines for incentive remuneration to
 vedtægter, udkast til opdaterede       the Management of the Company, draft    
 generelle retningslinjer for           updated remuneration policy for the     
 incitamentsaflønning af Selskabets     Board of Directors and the Executive    
 ledelse, udkast til opdateret          Management and the Nomination           
 vederlagspolitik for bestyrelsen og    Committee's recommendations about the   
 direktionen samt                       election of the members of the Board of 
 Nomineringskomitéens anbefalinger om   Directors.                              
 valg af medlemmer af bestyrelsen.                                              
Fremsendelse af indkaldelse            Publication of notice                    
Denne indkaldelse er ligeledes         This notice has also been made public via
 offentliggjort via                     the electronic system of the Danish     
 Erhvervsstyrelsens it-system, sendt    Business Authority, sent to the         
 til de i Selskabets ejerbog noterede   shareholders registered in the register 
 aktionærer samt offentliggjort på      of shareholders of the Company and made 
 Selskabets hjemmeside.                 public on the Company's website.        
                                                                                
Spørgsmål                              Questions                                
Aktionærer har mulighed for at stille  Shareholders may ask questions concerning
 spørgsmål til dagsordenen samt til     the agenda and the other material       
 det øvrige materiale til brug for      relating to the General Meeting both    
 generalforsamlingen både før og på     before and during the actual General    
 selve generalforsamlingen.             Meeting.                                
                                                                                
                - 0 -                                    - 0 -                  
                                                                                
For at kunne deltage på                In order to attend the General Meeting   
 generalforsamlingen og afgive stemme   and to vote the following apply:        
 gælder følgende:                                                               
                                                                                
Registreringsdato                      Date of registration                     
Aktionærernes ret til at møde og       The shareholders' right to attend and    
 afgive stemme på                       vote at the General Meeting, or to vote 
 generalforsamlingen, eller afgive      by post, is determined based on the     
 brevstemme, fastsættes i forhold til   shares which the shareholders hold at   
 de aktier, som aktionærerne besidder   the date of registration.               
på registreringsdatoen.                The date of registration is Tuesday 14   
Registreringsdatoen er tirsdag den      April 2015.                             
 14. april 2015.                                                                
                                                                                
Kun personer, der på                   Only persons, who are shareholders in the
 registreringsdatoen er aktionærer i    Company at the date of registration, may
 Selskabet, har ret til at deltage i    attend and vote at the General Meeting, 
 og stemme på generalforsamlingen,      however, see below regarding the        
 jf. dog umiddelbart nedenfor om        shareholders' request for admission     
 aktionærernes rettidige anmodning om   cards in due time.                      
 adgangskort.                                                                   
                                                                                
Ved udløb af registreringsdatoen       When the date of registration expires,   
 opgøres de aktier, som hver aktionær   the shares held by each shareholder will
 besidder. Opgørelsen sker på           be calculated. The calculation is based 
 baggrund af notering af aktier i       on the registration of shares in the    
 ejerbogen samt meddelelser om          register of shareholders as well as     
 ejerforhold, som Selskabet har         notifications of ownership which have   
 modtaget inden udløb af                been received by the Company before the 
 registreringsdatoen med henblik på     expiry of the date of registration for  
 notering i ejerbogen, men som endnu    the purpose of registration in the      
 ikke er indført i ejerbogen.           register of shareholders, but which have
                                        not yet been registered in the register 
                                        of shareholders.                        
                                                                                
Adgangskort                            Admission card                           
For at kunne møde på                   In order to attend the General Meeting   
 generalforsamlingen skal aktionæren    the shareholder must order an admission 
 senest den 17. april 2015 have         card no later than on 17 April 2015.    
 bestilt adgangskort. Adgangskort kan   Admission cards can be acquired by      
 bestilles hos Computershare A/S,       contacting Computershare A/S, Kongevejen
 Kongevejen 418, 2840 Holte, fax nr.    418, 2840 Holte, Denmark, fax no. +45 45
 45 46 09 98 eller via e-mail til       46 09 98 or by email to                 
 gf@computershare.dk.                   gf@computershare.dk. The registration   
 Tilmeldingsblanket til brug for        form to be used when ordering admission 
 bestilling af adgangskort er           cards is attached to the notice and is  
 vedhæftet indkaldelsen og kan findes   also available on the website of the    
 på Selskabets hjemmeside,              Company, www.zealandpharma.com. In      
 www.zealandpharma.com. Adgangskort     addition, admission cards can be ordered
 kan endvidere bestilles elektronisk    electronically on the website of the    
 via Selskabets hjemmeside,             Company, www.zealandpharma.com.         
 www.zealandpharma.com.                                                         
                                                                                
Fuldmagt                               Proxy                                    
En aktionær kan møde ved fuldmægtig.   A shareholder may be represented by      
 Fuldmagtsblanket skal være             proxy. Computershare A/S must receive   
 Computershare A/S i hænde senest den   the proxy form no later than on 17 April
 17. april 2015 enten ved returnering   2015 either by sending the form to      
 til Computershare A/S, Kongevejen      Computershare A/S, Kongevejen 418, 2840 
 418, 2840 Holte, Danmark, fax nr. 45   Holte, Denmark, fax no. +45 45 46 09 98 
 46 09 98 eller via e-mail til          or by email to gf@computershare.dk. The 
 gf@computershare.dk.                   proxy form is attached to the notice and
 Fuldmagtsblanket er vedhæftet          is available on the website of the      
 indkaldelsen og kan findes på          Company, www.zealandpharma.com. It is   
 Selskabets hjemmeside,                 also possible to submit an electronic   
 www.zealandpharma.com. Det er          proxy by visiting www.zealandpharma.com.
 ligeledes muligt at afgive                                                     
 elektronisk fuldmagt på                                                        
 www.zealandpharma.com.                                                         
                                                                                
Brevstemme                             Postal vote                              
Aktionærer kan, i stedet for at        Instead of casting one's vote at the     
 stemme på selve generalforsamlingen,   actual General Meeting, the shareholders
 vælge at brevstemme, dvs. at stemme    may vote by post, i.e. vote in writing  
 skriftligt, inden                      before the General Meeting is held. The 
 generalforsamlingen afholdes.          shareholders who decide to vote by post 
 Aktionærer, der vælger at stemme pr.   are to submit their vote by post so that
 brev skal sende deres brevstemme       it has been received no later than on 20
 således, at den er modtaget senest     April 2015 at noon to Computershare A/S,
 den 20. april 2015 kl. 12 til          Kongevejen 418, 2840 Holte, Denmark, fax
 Computershare A/S, Kongevejen 418,     no. +45 45 46 09 98 or by email to      
 2840 Holte, Danmark, fax nr. 45 46     gf@computershare.dk. The form to be used
 09 98 eller via e-mail til             when voting by post is attached to the  
 gf@computershare.dk.                   notice and is available on the website  
 Brevstemmeblanket er vedhæftet         of the Company, www.zealandpharma.com.  
 indkaldelsen og kan findes på          It is also possible to vote by post     
 Selskabets hjemmeside,                 electronically by visiting              
 www.zealandpharma.com. Det er          www.zealandpharma.com. A vote by post   
 ligeledes muligt at brevstemme         that has been received cannot be        
 elektronisk på                         revoked.                                
 www.zealandpharma.com. En                                                      
 brevstemme, som er modtaget, kan                                               
 ikke tilbagekaldes.                                                            
                - 0 -                                    - 0 -                  
                                                                                
Dato: 26. marts 2015                   Date: 26 March 2015                      
Med venlig hilsen                      Best regards                             
Bestyrelsen i Zealand Pharma A/S       The Board of Directors of Zealand Pharma 
                                        A/S                                     
                                                                                



Bilag 1 - Anbefaling fra                 Exhibit 1 - Recommendation from the    
 nomineringskomiteen                      Nomination Committee                  
Zealand har i henhold til §15 i          Zealand has, pursuant to §15 in the    
 selskabets vedtægter nedsat en           Articles of Association of the        
 nomineringskomité, bestående af 4        Company, appointed a Nomination       
 medlemmer, hvoraf 2 medlemmer er         Committee consisting of four members, 
 aktionærrepræsentanter valgt på          of which two are shareholder          
 generalforsamlingen.                     representatives elected at the Annual 
 Nomineringskomitéen skal vurdere         General Meeting. The purpose of the   
 bestyrelsens sammensætning og            Nomination Committee is to assess the 
 forelægge generalforsamlingen            composition of the Board of Directors 
 anbefalinger om valg af                  and to present annual recommendations 
 generalforsamlingsvalgte                 to the General Meeting about the      
 bestyrelsesmedlemmer.                    election of the board members to be   
Nomineringskomitéens medlemmer består     elected by the General Meeting.       
 af:                                     The member of the Nomination Committee 
-- Daniël J. Ellens, formand for          are:                                  
 bestyrelsen - formand for               -- Daniël J. Ellens, Chairman of the   
 nomineringskomitéen                      Board of Directors - Chairman of the  
-- Peter Benson, bestyrelsesmedlem       Nomination Committee                   
-- Bente Anderskouv, Head of Equities,   -- Peter Benson, member of the Board of
 Lønmodtagernes Dyrtidsfond -             Directors                             
Aktionærrepræsentant                     -- Bente Anderskouv, Head of Equities, 
-- Rémi Droller, Managing Partner,        Lønmodtagernes Dyrtidsfond -          
 Kurma Partners - Aktionærrepræsentant   Shareholder representative             
Aktionærrepræsentanterne er valgt på     -- Rémi Droller, Managing Partner,     
 generalforsamlingen i 2014 for en        Kurma Partners - Shareholder          
 3-årig periode.                          representative                        
Formanden, Daniël Jan Ellens, og         The shareholder representatives were   
 næstformanden, Jørgen Lindegaard, har    elected at the General Meeting in 2014
 meddelt at de ikke genopstiller til      for a period of three years.          
 bestyrelsen. Desuden udtrådte Florian   The current chairman, Daniël Jan       
 Reinaud af bestyrelsen i februar 2015.   Ellens, and the current vice chairman,
Nomineringskomiteen anbefaler at          Jørgen Lindegaard has decided not to  
 generalforsamlingen genvælger Peter      run for re-election. Further, Florian 
 Benson, Alain Munoz og Michael J.        Reinaud stepped down from the board in
 Owen. Ligeledes anbefaler                February 2015.                        
 nomineringskomiteen at                  The Nomination Committee recommends to 
 generalforsamlingen vælger Rosemary      re-elect Peter Benson, Alain Munoz and
 Crane, Catherine Moukheibir og Martin    Michael J. Owen, and in addition to   
 Nicklasson til bestyrelsen. Nedenfor     elect Rosemary Crane, Catherine       
 er præsenteret yderligere oplysninger    Moukheibir and Martin Nicklasson to   
 om de opstillede kandidater.             the Board of Directors. Below please  
                                          find a presentation of the nominated  
                                          candidates.                           
Kandidater nomineret til                 Nominated candidates to the Board of   
Bestyrelsen                               Directors                             
Peter Benson - Bestyrelsesmedlem         Peter Benson - Board member            
Peter Benson (1955) har været medlem af  Peter Benson (1955) has been member of 
 bestyrelsen siden 2007, og fungerede     the Board since 2007, and served as   
 som næstformand i perioden 2010-2011.    Vice Chairman 2010-2011. He is        
 Han anses som et uafhængigt medlem af    regarded as an independent board      
 bestyrelsen.                             member.                               
Peter Benson er Managing Partner i       Peter Benson is Managing Partner of    
 Sunstone Capital og fungerede            Sunstone Capital and earlier was      
 tidligere som leder af Vækstfonden       Partner and Head of Vækstfonden Life  
 Life Science Ventures. Forud for         Science Ventures from 2003. Prior to  
 grundlæggelsen af ​​Sunstone Capital i   founding Sunstone Capital in 2007, he 
 2007, har han været mere end 20 år i     spent more than 20 years in the life  
 life science industrien, inklusiv som    science industry, including as        
 koncerndirektør i Pharmacia og chef      President of Pharmacia and Manager for
 for divisionen Hospital Care. Peter      the division Hospital Care. He also   
 har også været medlem af en række        served on a number of Life Science    
 bestyrelser herunder de børsnoterede     boards, including the currently public
 selskaber Biogaia (Sverige), Ortivus     listed companies Biogaia (Sweden),    
 (Sverige), Cellavision AB (Sverige) og   Ortivus (Sweden), Cellavision AB      
 Optovent AB (Sverige). Han er medlem     (Sweden) and Optovent AB (Sweden). He 
 af bestyrelsen for Asante Solutions      serves as a member of the Board of    
 Inc. (USA), Arcoma AB (Sverige),         Asante Solutions Inc. (USA), Arcoma AB
 Alligator Bioscience AB (Sverige) og     (Sweden), Alligator Bioscience AB     
 Opsona Threapeutics Ltd (Irland).        (Sweden) and Opsona Therapeutics Ltd  
Peter Benson har en Bachelor i Business   (Ireland).                            
 Administration fra Lunds Universitet    Peter Benson holds a Bachelor of       
 og en MA i økonomi fra University of     Business Administration from the      
 California.                              University of Lund and a M.A. in      
Rosemary Crane - Bestyrelsesmedlem        Economics from the University of      
Rosemary Crane (1960) opstiller som       California.                           
 kandidat til bestyrelsen for første     Rosemary Crane - Board member          
 gang og anses som uafhængigt medlem.    Rosemary Crane (1960) is proposed      
Rosemary Crane har fungeret som           elected to the Board of Directors, and
 administrerende direktør i Mela          is regarded as an independent board   
 Sciences (2013-14) og Epocrates          member.                               
 (2008-2011), og har derudover haft      Rosemary Crane has been CEO of Mela    
 ledende stillinger i Johnson             Sciences (2013-14) and Epocrates      
 & Johnson og BMS. Rosemary   (2008-2011), besides having held a    
 har særligt erfaring indenfor            number of leading positions in Johnson
 marketing og har en solid forståelse     & Johnson and BMS. She has
 indenfor mange områder, bl.a.            a background in marketing and has a   
 hjerte-kar sygdomme og diabetes.         knowledge base in diabetes and        
Rosemary Crane er medlem af det           cardiovascular disease among others.  
 rådgivende udvalg på Oswego State       Rosemary Crane is a member of the      
 University Business School, The          Advisory Board of Oswego State        
 Foundation Board på Oswego State         University Business School, The       
 University, samt medlem af Transplant    Foundation Board of Oswego State      
 House Committee på University of         University and the Transplant House   
 Pennsylvania.                            Committee at University of            
Rosemary Crane har en Bachelor i          Pennsylvania.                         
 kommunikation fra State University of   Rosemary Crane holds a BA in           
 New York, og en MBA fra Kent State       communication from the State          
 University.                              University of New York and an MBA from
Catherine Moukheibir -                    Kent State University.                
 Bestyrelsesmedlem                       Catherine Moukheibir - Board member    
Catherine Moukheibir (1959) opstiller    Catherine Moukheibir (1959) is proposed
 som kandidat til bestyrelsen for         elected to the Board of Directors, and
 første gang og anses som uafhængigt      is regarded as an independent board   
 medlem.                                  member.                               
Catherine Moukheibir er senior rådgiver  Catherine Moukheibir is member of the  
 og medlem af ledelsen i Innate Pharma.   management board at Innate Pharma.    
 Hun startede sin karriere som            Before that she held senior management
 konsulent indenfor strategi og           positions in several European biotech 
 investment banking og har siden haft     companies after an initial career in  
 flere stillinger på ledende niveau i     strategy consulting and investment    
 forskellige Europæiske biotek            banking in Boston and London. Her     
 virksomheder. Hun har derigennem         particular experience lies in aligning
 oparbejdet solid erfaring med at         corporate and financial strategy at   
 tilpasse den finansielle og den          various stages of a biotech's         
 overordnede virksomhedsstrategi i de     development, and she is currently a   
 forskellige stadier som biotek           non-executive Board member of         
 virksomheder gennemgår. Catherine        Creabilis and Ablynx.                 
 Moukheibir er bestyrelsesmedlem i       Catherine Moukheibir holds an MBA from 
 Creabilis og Ablynx.                     Yale University.                      
Catherine Moukheibir har en MBA fra      Alain Munoz - Board member, Chairman of
 Yale University.                         the Clinical and Scientific Advisory  
Alain Munoz - Bestyrelsesmedlem, samt     Board                                 
 Formand for det Kliniske og             Alain Munoz (1949) has been member of  
 Videnskabelige Råd                       the Board since 2005 (resigned in     
Alain Munoz (1949) har været medlem af    2006, and re-elected in 2007), and is 
 bestyrelsen siden 2005 (fratrådt i       not an independent member.            
 2006, og genvalgt i 2007), og anses     Alain Munoz is CEO and founder of      
 som et ikke-uafhængigt                   Amistad Pharma S.A.S. (France) and    
 bestyrelsesmedlem.                       Science, Business and Management SARL 
Alain Munoz er administrerende direktør   (France), and has over 20 years of    
 og grundlægger af virksomhederne         experience in the pharmaceutical      
 Amistad Pharma SAS (Frankrig) og         industry at senior management level.  
 Science, Business and Management SARL    Within the Sanofi Group he served as  
 (Frankrig). Han har over 20 års          SVP for International development     
 erfaring fra den farmaceutiske           (France) and in Fournier Laboratories 
 industri med flere stillinger på         as SVP for the Pharmaceutical division
 ledende niveau. I Sanofi koncernen       (France). He is a member of the Board 
 fungerede han som SVP for                of Valneva SA (France), Auris Medical 
 international udvikling (Frankrig), og   AG (Switzerland) and Medesis Pharma SA
 i Fournier Laboratories som SVP for      (France).                             
 Pharmaceutical division (Frankrig).     Alain Munoz holds an MD in Cardiology  
 Han er medlem af bestyrelsen for         and Anaesthesiology from the Hospital 
 Valneva SA (Frankrig), Auris Medical     Pitié-Salpétrière, Paris. He has      
 AG (Schweiz) og Medesis SA (Frankrig).   numerous publications and has been a  
Alain Munoz er Dr. Med. i kardiologi og   member of the scientific committee of 
 anæstesi fra Hospital                    the French Drug Agency.               
 Pitié-Salpétrière, Paris. Han har       Martin Nicklasson - Board member       
 været medforfatter på talrige           Martin Nicklasson (1955) is proposed   
 publikationer og har været medlem af     elected to the Board of Zealand, and  
 det videnskabelig udvalg under den       is regarded as an independent board   
 franske lægemiddelstyrelse (French       member.                               
 Drug Agency).                           Martin Nicklasson has held various     
Martin Nicklasson - Bestyrelsesmedlem     Executive Vice President positions at 
Martin Nicklasson (1955) opstiller som    AstraZeneca Plc and has served as     
 kandidat til bestyrelsen for første      President and CEO of Biovitrum AB and 
 gang og anses som uafhængigt medlem.     Swedish Orphan Biovitrum AB. Prior to 
Martin Nicklasson har fungeret som        this he held a number of leadership   
 administrerende direktør for Biovitrum   positions at Astra and Kabi Pharmacia.
 AB og Swedish Orphan Biovitrum AB i      Martin Nicklasson is chairman of the  
 perioden 2009-2011, og har derudover     board of Orexo AB, Farma Holding and  
 haft adskillige ledende stillinger i     Basilea Pharmaceutica Ltd. He serves  
 virksomheder som AstraZeneca, Astra og   as a board member in Biocrine AB,     
 Kabi Pharmacia. Martin Nicklasson er     PledPharma AB and Premier Research    
 bestyrelsesformand for Orexo AB, Farma   Group Ltd., and is also on the board  
 Holding og Basilea Pharmaceutica Ltd,    of the Swedish Heart and Lung         
 og medlem af bestyrelsen i Biocrine      foundation.                           
 AB, PledPharma AB, Premier Research     Martin Nicklasson is a certified       
 Group Ltd., samt i Sveriges Hjerte og    pharmacist and holds a PhD in         
 Lunge Forening.                          Pharmaceutical Technology from the    
Martin Niklasson er uddannet Farmaceut    Uppsala University, where he is       
 og har en PhD i teknologisk farmaci      Associate Professor at the Department 
 fra Uppsala Universit, hvor han stadig   of Pharmaceutics.                     
 fungerer som lektor.                    Michael J. Owen - Board member         
Michael J. Owen - Bestyrelsesmedlem      Michael J. Owen (1951) was elected to  
Michael J. Owen (1951) blev valgt til     the Board of Directors in 2012, and is
 bestyrelsen i 2012 og anses som          regarded as an independent board      
 uafhængigt medlem.                       member.                               
Michael J. Owen er medstifter af Kymab   Michael J. Owen is a co-founder and was
 Ltd (Storbritannien) og fungerede der    CSO at Kymab Ltd. (UK). Before joining
 som forskningsdirektør. Før Kymab,       Kymab, he had several leading         
 havde han flere ledende stillinger hos   positions at GlaxoSmithKline, latterly
 GlaxoSmithKline, senest som SVP og       as SVP and head of biopharmaceuticals 
 leder af den biofarmaceutiske            research. Prior to joining GSK in     
 forskning. Før han kom til GSK i 2001,   2001, he headed the Lymphocyte        
 ledede han lymfocyt molekylær biologi    Molecular Biology group at the        
 gruppen ved Imperial Cancer Research     Imperial Cancer Research Fund. He has 
 Fund. Han har mere end 20 års            more than 20 years of research        
 forskningserfaring med fokus på          experience with a focus on the immune 
 immunsystemet. Han er medforfatter på    system. He has more than 150          
 mere end 150 publikationer og er         publications and membership of the    
 medlem af European Molecular Biologi     European Molecular Biology            
 Organisation og af Academy of Medical    Organisation and Fellowship of the    
 Sciences. Han er medlem af bestyrelsen   Academy of Medical Sciences. He is a  
 i Ossianix, Inc. (USA) og BLINK          member of the Board of Ossianix, Inc. 
 Biomedical SAS (UK).                     (USA) and BLINK Biomedical SAS (UK).  
Michael J. Owen har en PhD i aminosyre   Michael J. Owen holds a PhD in amino   
 transport i trypanosomer fra Cambridge   acid transport in trypanosomes from   
 University, og en BA i biokemi fra       Cambridge University, and a BA in     
 Keble College, Oxford University.        Biochemistry from Keble College,      
                                          Oxford University.
News Source: NASDAQ OMX



26.03.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Zealand Pharma A/S
              
               
              Denmark
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         DK0060257814
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------